3 recruiting, 2 completed, 1 active not recruiting, 1 terminated. 3 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Terminated 1 |
| Phase 3 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Primary Peritoneal Clear Cell Adenocarcinoma: new trials by email Literature Review of Primary Peritoneal Clear Cell Adenocarcinoma trials Research Report on Primary Peritoneal Clear Cell Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial Biopsy, Biospecimen Collection, Computed Tomography - Advanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Recruiting | Mayo Clinic | 78 | 2024-11-12 | 2026-10-02 |
| APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion Bevacizumab, Biopsy, Biospecimen Collection - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 60 | 2023-04-27 | 2026-03-23 |
| Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial Chemotherapy, Laparotomy, Minimally Invasive Surgery - Advanced Ovarian Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 3 | Recruiting | M.D. Anderson Cancer Center | 580 | 2020-08-05 | 2026-09-14 |
| MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Bevacizumab, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Terminated | Mayo Clinic | 17 | 2015-03-13 | 2025-12-11 |
| Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers Bevacizumab, Laboratory Biomarker Analysis, Nab-paclitaxel - Cervical Adenocarcinoma, Cervical Adenosarcoma | Phase 1 | Completed | Mayo Clinic | 43 | 2014-02-24 | 2024-07-26 |
| Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Bevacizumab, Carboplatin, Cisplatin - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 1560 | 2009-08-11 | 2026-06-02 |
| Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Docetaxel - Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1052 | 2007-12-06 | 2025-12-30 |
Fallopian Tube Neoplasms (4) · Ovarian Neoplasms (4) · Brenner Tumor (2) · Adenocarcinoma, Clear Cell (1) · Adenocarcinoma, Mucinous (1) · Carcinoma (1)
Adnexal Diseases (5) · Endocrine System Diseases (5) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Genital Diseases (5) · Genital Diseases, Female (5) · Genital Neoplasms, Female (5) · Gonadal Disorders (5) · Neoplasms (5) · Ovarian Diseases (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Endocrine Gland Neoplasms (4) · Fallopian Tube Diseases (4) · Neoplasms by Site (4)
Bevacizumab (5) · Disulfides (5) · Immunoglobulin G (5) · Taxes (4) · Paclitaxel (3) · Biopsy (2) · Carboplatin (2) · Gemcitabine (2) · Specimen Handling (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Cisplatin (1) · Diphtheria Toxoid (1) · Diphtheria-Tetanus Vaccine (1)
Mayo Clinic (3) · National Cancer Institute (NCI) (2) · M.D. Anderson Cancer Center (1) · Roswell Park Cancer Institute (1)
United States (7) · Canada (1) · Italy (1) · Japan (1) · Mexico (1) · Netherlands (1) · South Korea (1)
Emese Zsiros (1) · Evanthia Galanis, M.D. (1) · Joan L Walker (1) · Jose A Rauh-Hain (1) · Matthew S. Block, M.D., Ph.D. (1) · Matthew S. Block, MD, PhD (1) · Robert L Coleman (1)
PMID 28438473, PMID 31002578, PMID 31722153, PMID 37185961, PMID 39570589
U10CA027469 (2), U10CA180868 (2), R01CA267690 (1)